9-fold , respectively, compared to administration alone. The
interaction has also been reported in patients receiving atorvastatin, lovastatin, or simvastatin with other potent CYP450 3A4 inhibitors such as azole antifungal agents, macrolide antibiotics, HIV protease inhibitors, and nefazodone. Clinically, high levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity.